Neonatal necrotizing enterocolitis

Akhil Maheshwari1
Laura L Corbin2
Robert L Schelonka2
1Division of Neonatology and Center for Neonatal and Pediatric Gastrointestinal Disease, Department of Pediatrics, University of Illinois at Chicago, IL, 2Division of Neonatology, Department of Pediatrics, Oregon Health and Sciences University, Portland, OR, USA

Abstract: Necrotizing enterocolitis is the most common gastrointestinal emergency in preterm neonates and a major cause of morbidity and mortality in premature infants born before 32 weeks of gestation or with a birth weight less than 1500 g. In this review, we discuss predisposing factors, clinical manifestations, and the quality of evidence for various preventive and therapeutic strategies.

Keywords: necrotizing enterocolitis, inflammation, mucosa, pneumatosis, neonate

Introduction

Necrotizing enterocolitis (NEC), an inflammatory bowel necrosis of infants,1,2 is the most common gastrointestinal emergency in preterm neonates and a major cause of morbidity and mortality in neonatal intensive care units throughout the world.3,4 In this review, we discuss pathophysiological factors that may predispose the developing intestine to NEC, describe the clinical manifestations of this disease, and provide a critical appraisal of therapeutic strategies.

Incidence and epidemiology

The incidence of NEC is estimated to be 1–3 per 1000 live births, with more than 90% of all cases occurring in preterm infants.1 NEC occurs in 4%–11% of all premature infants born with very low birth weight (<1500 g), and the frequency in this subgroup is also inversely related to birth weight and gestational age.5,6 In the National Institute of Child Health and Development cohort at neonatal research network centers, NEC was recorded in 11.5%, 9%, 6%, and 4% of infants weighing 401–750 g, 751–1000 g, 1001–1250 g, and 1251–1500 g, respectively.7

The incidence of NEC varies significantly between neonatal intensive care units.8–11 Cases occur in each individual neonatal intensive care unit at an “endemic” rate specific for that unit, which may show some seasonal fluctuation and may be punctuated by minor epidemics.7,12–15 Although the reasons for these center differences are unclear, plausible explanation(s) include biological differences in patient populations and distribution of birth weights, infectious milieu in the neonatal intensive care units, and consistency in labeling of cases that recover without requiring significant medical or surgical intervention.15

Despite improvements in neonatal intensive care and increased overall survival of critically ill premature neonates, mortality rates from NEC can reach 50%.5,16,17 Most
Pathophysiology

Although the etiopathogenesis of NEC remains unclear, current epidemiological and experimental evidence identifies several diverse risk factors and supports a multifactorial model of disease (summarized in Figure 1).

Prematurity is the most important predictor of NEC. Immaturity of the gastrointestinal tract, particularly in the context of its motility, digestion, perfusion, barrier function, and immune defense, is a major predisposing factor for NEC. The pathophysiological importance of prematurity is evident from the near exclusive occurrence of NEC in preterm infants, even though events generally considered to be critical in the pathogenesis of NEC, such as gut mucosal injury, altered barrier function, and bacterial translocation, are recorded frequently in critically ill patients of all ages.

Evidence for genetic predisposition to NEC is modest. Bhandari et al recorded NEC in one or both twins in nine of 63 (14%) pairs of monozygotic twins and in 29 of 189 (15%) pairs of dizygotic twins. After controlling for covariates, genetic factors did not account for any variance in liability for NEC. NEC has been associated with single nucleotide polymorphisms in the interleukin (IL)-4 receptor (1902G, protective), IL-18 (-607A, increased severity), vascular endothelial growth factor (+450C, increased risk), and the carbamoyl-phosphate synthetase 1 genes (T450N, increased risk). In contrast, NEC is not associated with most single nucleotide polymorphisms that have been linked with Crohn’s disease and ulcerative colitis, such as those in the genetic sequences of tumor necrosis factor-alpha (TNF-α), IL-1, IL-4, IL-6, IL-8, and IL-10, CD14, toll-like receptor 4, caspase-recruitment domain 15, and nucleotide-binding oligomerization domain containing 2.

NEC usually occurs in infants who are receiving enteral feedings. Although NEC can occur in neonates who have never been fed, 90%–95% of cases occur in infants with a history of recent volume advancement or reinitiation of enteral feedings. Besides the risk of direct osmotic injury to the gut mucosa, feedings may also alter splanchnic blood flow and increase the risk of ischemic injury in underperfused regions by increasing local oxygen needs. In addition, immaturity of motility and digestion in the developing intestine may leave undigested food in the lumen for prolonged periods, promoting bacterial overgrowth and translocation. Products of bacterial fermentation, such as short chain fatty acids, can also injure the immature gut mucosa.

Infants receiving formula feedings are at increased risk of NEC compared with exclusively breastfed neonates. Formula lacks both cellular as well as soluble immunoprotective factors, such as IgA and various natural antimicrobials, and also has a propensity to alter the normal postnatal gut bacterial colonization. Recent studies indicate that formula feeding in newborn animals may directly induce inflammatory changes in the gut mucosa.

Figure 1 Current epidemiological and experimental information on necrotizing enterocolitis supports a multifactorial model of disease. Clinical and histopathological features indicate that tissue ischemia, bacterial flora, a dysregulated inflammatory response, and enteral feedings may contribute to the pathogenesis of necrotizing enterocolitis in premature infants.

Abbreviations: IL, interleukin; VEGF, vascular endothelial growth factor; PAF, plasminogen activating factor; TNFα, tumor necrosis factor alpha.
In spite of a large body of data from physiological and retrospective studies, a direct association between specific feeding regimens and/or the rapidity of advancement of feed volumes and NEC has not been conclusively proven. Several observational studies have suggested that delaying the introduction of enteral feeds beyond the first few days after birth, and using standardized regimes to increase the volume of feeds by less than about 24 mL/kg body weight each day may be associated with a lower risk of NEC. In the National Institute of Child Health and Development neonatal research network, the incidence of NEC was higher at centers where enteral feeding was introduced earlier and feeding volumes advanced rapidly. In a recent retrospective study from a multihospital system, fulminant NEC characterized by massive bowel necrosis and rapid progression to death within 48 hours was associated with advancement of feedings by more than 20 mL/kg/day and/or an increase in concentration of human milk fortifier within 48 hours before developing NEC. However, the association between aggressive enteral feeding and NEC has not been evident in randomized controlled trials comparing slow versus rapid advancement of feedings. A meta-analysis based on these studies showed that cautiously advanced enteral feedings are not only safe, but may also reduce other morbidities associated with prematurity. Similarly, current trial data do not provide evidence that delayed introduction of progressive enteral feed reduces the risk of NEC in very low birth weight infants. In a meta-analysis of five randomized controlled trials (600 infants, delayed introduction of feedings defined as later than 5–7 days after birth, and early introduction as less than 4 days after birth), delayed introduction of feedings did not reduce the risk of NEC (relative risk [RR] 0.89, 95% confidence interval [CI] 0.58–1.37) or all-cause mortality (RR 0.93, 95% CI 0.53–1.64). Infants who had delayed introduction of enteral feeds took significantly longer to establish full enteral feeding (reported median difference 3 days).

Mucosal injury may be an early event. Gut epithelial injury is believed to be an early event in NEC. Although the causes of this initial epithelial injury remain unclear, primary apoptotic and autophagic mechanisms have been invoked. This disruption of the epithelial barrier is presumed to allow bacterial translocation, which in turn triggers a local inflammatory response. Ischemia may play a role in NEC. Coagulative necrosis, which is typically associated with ischemia, is a prominent histopathological finding in NEC. The predilection for the ileocecal region, a watershed area supplied by end-arteries, also indicates that ischemia may be an important pathophysiological event in NEC. Infants with NEC may have decreased endothelial nitric oxide synthase activity and decreased arteriolar nitric oxide production, which can place the developing intestine at a higher risk of ischemic injury. However, this association between hypoxia-ischemia and NEC has not been clearly established in clinical studies in preterm infants. Although minor transient episodes of hypoxia and/or hypotension are not uncommon in premature neonates, major ischemic events are obvious in only a minority of preterm infants with NEC, and tend to occur early in the neonatal period rather than in postnatal weeks 2–4 when NEC occurs.

In full-term infants, NEC tends to occur at an earlier postnatal age than in preterm infants, and is more obviously associated with factors that may conceivably cause splanchic hypoperfusion. Many term or near-term infants with NEC have a history of placental insufficiency and absence/reversal of end-diastolic blood flow in the umbilical vessels in utero, perinatal asphyxia, polycythemia, episodes of low cardiac output or clinical shock, and congenital cyanotic heart disease. NEC is characterized by a severe, unregulated inflammatory response. It is characterized by a prominent leukocyte infiltrate comprised of activated macrophages and neutrophils. Human and animal studies have demonstrated increased tissue expression of TNFα and platelet activating factor (PAF), which may propagate ongoing mucosal injury by triggering a cascade of inflammatory mediators, including IL-1, IL-6, IL-8, IL-10, IL-12, and IL-18. Activation of the complement and coagulation cascades, cytokines, reactive oxygen species, and nitric oxide further amplify the mucosal injury. In infants with NEC, increased expression of PAF may be coupled with reduced levels of PAF acetylhydrolase (the enzyme which degrades PAF), further augmenting its local inflammatory effects. In experimental animals, attempts to regulate the inflammatory response by depletion of neutrophils or by using anti-TNFα antibodies have successfully reduced the severity of tissue damage.

Bacteria play an essential role in the pathogenesis of NEC. Several lines of evidence emphasize the importance of bacterial flora in the pathogenesis of NEC: NEC occurs only after postnatal bacterial colonization of the gastrointestinal tract; intestinal injury prior to colonization may cause strictures or atresia, but not NEC; pneumatosis intestinalis, the pathognomonic finding in NEC, reflects the entrapment of the gaseous products of bacterial fermentation in affected...
Immaturity of Paneth cells, specialized crypt cells that produce natural antimicrobials (such as enteric human defensins 5 and 6) and MD2 (a key component of the lipopolysaccharide receptor complex), has been suggested to contribute to the risk of NEC. Acute NEC is associated with a low number of Paneth cells, which show weak immunoreactivity or complete absence of lysozyme. During recovery from NEC, Paneth cell hyperplasia/metaplasia has been observed with increased expression of enteric defensins.

Secretory IgA (sIgA) antibodies are an important host defense mechanism, preventing luminal antigens and microorganisms from entering the mucosa. In an adult human subject, 70%–80% of all Ig-producing cells in the body are located in the intestinal mucosa and most of these cells produce IgA. However, neonates lack IgA immunocytes at birth and the first sIgA may not appear in mucosal secretions until sometime between postnatal week 2 and 8. This deficiency can be partially offset in breastfed infants by sIgA present in colostrum/milk; breastfed infants receive about 0.5–1.0 g/day of antibodies in milk throughout lactation, which is comparable with the 2.5 g daily production of antibodies by a 65 kg adult, and a source of passive immunity against antigens “seen” by the mother-infant dyad. In formula-fed premature infants, the absence of milk-borne sIgA is a significant immunological disadvantage and a likely contributor to the increased risk of NEC.

Compared with term infants, premature neonates have increased gut mucosal permeability, and this permeability is even greater in infants who subsequently develop NEC. Studies on human tissue samples and in rodent models show that the intestinal epithelium is breached early during NEC through apoptosis or necrosis. In this process, excessive nitric oxide production, either directly or through its reactive nitrogen derivative, peroxynitrite, may accentuate epithelial injury through membrane oxidation, induction of apoptosis, and direct mitochondrial damage. In preterm infants, a deficiency in the mucus layer may promote bacterial adherence and increase gut mucosal permeability, predisposing to mucosal injury. The developmental deficiency of epithelial trophic factors, such as the epidermal growth factor and heparin-binding epidermal growth factor-like growth factor, may further increase the risk of injury to the epithelial barrier.

Do red blood cell transfusions predispose to NEC? In convalescing preterm infants, red blood cell transfusions have
been temporally associated with NEC.\textsuperscript{113,115} Red blood cell transfusions can dampen the normal postprandial increase in mesenteric blood flow in premature infants, particularly in those with a birth weight $<$1250 g.\textsuperscript{120} Immaturity of vascular autoregulation in extremely preterm infants is linked to defects in endothelial nitric oxide synthesis\textsuperscript{68} and could plausibly explain a higher risk of mucosal injury following transfusions.

### Pathology

The disease is commonly localized to the ileocolic region, although the colon may be frequently involved in term infants.\textsuperscript{121} Some infants with severe, aggressive disease may develop total gut necrosis (NEC totalis). The four major histopathological findings in NEC are coagulative necrosis, bacterial overgrowth, pneumatosis intestinalis, and inflammation.

### Clinical features

The presenting signs of NEC are protean and may be insidious in onset or sudden and catastrophic. NEC typically presents at 2–4 weeks after birth, although the onset may be as late as 3 months in some infants.\textsuperscript{16,72,122} The age of onset of NEC correlates inversely with gestational age at birth in a nonlinear (log-normal) relationship, where infants born at 2–4 weeks after birth, although the onset may be as late as 3 months in some infants.\textsuperscript{16,72,122} The age of onset of NEC correlates inversely with gestational age at birth in a nonlinear (log-normal) relationship, where infants born at $<$28 weeks’ gestation tend to develop NEC at a disproportionately greater postnatal age than their more mature counterparts.\textsuperscript{123,124}

NEC often presents with nonspecific systemic signs, such as tachycardia, apnea, lethargy, and temperature instability. Gastrointestinal signs may include increased prefeed residuals or delayed gastric emptying, emesis, abdominal distention, tenderness, and/or ileus with hypoaemic bowel sounds. Grossly bloody stools are seen in approximately 25% of infants. Clinical progression of NEC is commonly staged using the modified Bell’s criteria (Table 1).\textsuperscript{125} Characteristically, NEC follows an initial early stage of systemic inflammatory response, followed by a definite stage of localized peritonitis, and finally, an advanced stage of generalized peritonitis.

In a recent study, Clark et al\textsuperscript{126} described the clinical characteristics of infants who died of NEC. Compared with 5594 infants who recovered from NEC and were discharged home, there were 1505 infants diagnosed with NEC who died. In multivariate analysis, lower gestational age, lower birth weight, treatment with assisted ventilation on the day of diagnosis of NEC, treatment with vasopressors at the time of diagnosis, and African-American ethnicity were associated with mortality. In another study,\textsuperscript{58} fulminant NEC, characterized by massive bowel necrosis and rapid progression to death within 48 hours, was recorded in 7%–10% of all cases and was associated with lower birth weight (1088 ± 545 g versus 1652 ± 817 g), earlier gestational age (27.5 ± 3.3 weeks versus 31.1 ± 4.4 weeks), radiographic evidence of portal venous air, hematocrit <22%, a history of advancement in feeding volume $>$20 mL/kg/day, an immature to total neutrophil ratio $>$0.5, blood lymphocyte count $<$4000/µL, and a history of increased concentration of

<table>
<thead>
<tr>
<th>Stage</th>
<th>Classification</th>
<th>System signs</th>
<th>Intestinal signs</th>
<th>Radiological signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>Suspected NEC</td>
<td>Temperature instability, apnoea, bradycardia, lethargy</td>
<td>Increased pregavage residuals, mild abdominal distention, emesis, guaiac-positive stool</td>
<td>Normal or intestinal dilation, mild ileus</td>
</tr>
<tr>
<td>IB</td>
<td>Suspected NEC</td>
<td>Same as above</td>
<td>Bright-red blood from rectum</td>
<td>Same as above</td>
</tr>
<tr>
<td>IIA</td>
<td>Proven NEC – mildly ill</td>
<td>Same as above</td>
<td>Same as above, plus absent bowel sounds, with or without abdominal tenderness</td>
<td>Intestinal dilation, ileus, pneumatosis intestinalis</td>
</tr>
<tr>
<td>IIB</td>
<td>Proven NEC – moderately ill</td>
<td>Same as above, plus mild metabolic acidosis and mild thrombocytopenia</td>
<td>Same as above, plus absent bowel sounds, definite abdominal tenderness, with or without abdominal cellulitis or right lower quadrant mass</td>
<td>Same as IIA, plus portal vein gas, with or without ascites</td>
</tr>
<tr>
<td>IIIA</td>
<td>Advanced NEC – severely ill, bowel intact</td>
<td>Same as IIB, plus hypotension, bradycardia, severe apnoea, combined respiratory and metabolic acidosis, disseminated intravascular coagulation, and neutropenia</td>
<td>Same as above, plus signs of generalized peritonitis, marked tenderness, and distention of abdomen</td>
<td>Same as IIB, plus definite ascites</td>
</tr>
<tr>
<td>IIIB</td>
<td>Advanced NEC – severely ill, bowel perforated</td>
<td>Same as IIIA</td>
<td>Same as IIIA</td>
<td>Same as IIB, plus pneumoperitoneum</td>
</tr>
</tbody>
</table>

**Note:** This table was published in *Pediatric Clinics of North America*, Vol 33, MC Walsh, RM Kliegman, Necrotizing enterocolitis: Treatment based on staging criteria, Pages 179–201, © Copyright Elsevier 1986.

**Abbreviation:** NEC, necrotizing enterocolitis.
human milk fortifier within 48 hours before developing NEC. In another study of NEC totalis, breast milk feeding was noted to have a protective effect.

NEC in full-term infants differs from that seen in premature infants. Approximately 10% of infants with NEC are born at term. Unlike preterm infants who develop NEC in the second or third week of life (median 12 days), most term cases are seen within the first week (median 2 days) and often have colonic involvement. NEC in term infants is usually secondary, associated with conditions such as birth asphyxia, polycythemia, congenital heart disease, rotavirus infections, and Hirschsprung’s disease. Outcomes are generally better than in preterm neonates, with mortality rates of 0%–13%.

Diagnosis

A high index of suspicion in diagnosing at-risk infants is crucial. Most clinical antecedents prior to Bell stage III NEC are nonspecific for gastrointestinal pathology and may not provide sufficient time to the clinician for early institution of treatment measures. In a recent retrospective study, Christensen et al reviewed the medical records of 118 infants with stage III NEC. The earliest recognized antecedents of NEC were nonspecific, including apnea/bradycardia, skin mottling, and irritability, which were first noted at a mean of 2.8 ± 2.1, 4.5 ± 3.1, and 5.4 ± 3.7 hours, respectively, prior to the diagnosis of NEC. The most frequently identified gastrointestinal antecedents were blood in the stools, increased abdominal girth, and elevated prefeeding gastric residuals or emesis, identified 2.0 ± 1.9, 2.8 ± 3.1, and 4.9 ± 4.0 hours before NEC was recognized. No consistent laboratory antecedents were discovered.

Radiographic features remain the mainstay of definitive diagnosis. The pathognomonic sign for NEC is pneumatosis intestinalis (Figure 2). These radiolucent shadows have a bubbly appearance when air is submucosal and become linear when subserosal. Portal venous gas has been associated with a poor prognosis, although this association has recently been questioned. Sonographic appearance of portal air is an early sign. In a prospective cohort study, sonographic portal air had a specificity of 86% for advanced NEC (≥ stage II), and the sensitivity was lower at 45%. It is not known if portal venous gas visualized by ultrasound or on plain radiographs has the same prognostic significance. Sonographic detection of echoic free fluid and bowel wall thinning may also be more sensitive for intestinal perforation than plain radiography. Serial radiographs are invaluable in following the progression of NEC, particularly in the first 48 hours after onset of disease.

Although intestinal perforation may occur within a few hours to as late as 8 days following the onset of NEC, more than two-thirds of all perforations occur within 30–48 hours. In some infants who present with bloody stools but minimal systemic signs, pneumatosis may be limited to the colon and may indicate a relatively benign course.

Most patients with NEC develop leukocytosis and neutrophilia, although neutrophils can occur in advanced disease due to the migration of neutrophils into the peritoneal cavity. Blood cultures may grow organisms typically associated with late-onset sepsis. Thrombocytopenia may occur in stage II and III, and patients with advanced NEC may have evidence of disseminated intravascular coagulation. Breath hydrogen testing was initially heralded as a diagnostic tool, but subsequent studies have shown it as lacking discriminant value.

The differential diagnosis of NEC includes infections (systemic or intestinal), gastrointestinal obstruction, volvulus, and isolated intestinal perforation. Idiopathic focal intestinal perforations can occur spontaneously or in association with deficiency of the muscularis propria, early use of postnatal corticosteroids alone or with indomethacin, and with occult candidal infections. Pneumoperitoneum develops in such patients, but they are usually less ill than those with NEC. Some experts believe that isolated perforations may not be related to NEC.
**Treatment**

**Medical management**

Rapid initiation of therapy is necessary for suspected as well as proven cases of NEC. There is no definitive treatment for established NEC, and therefore treatment is directed at supportive care and prevention of further injury with cessation of feeding, nasogastric decompression, and administration of intravenous fluids (see Table 2). Infants are usually made nil per os for a variable period of time, depending on the severity of disease. Parenteral antibiotics are widely used for the treatment of NEC.

**Table 2** Treatment and prevention of necrotizing enterocolitis

<table>
<thead>
<tr>
<th>Therapeutic intervention</th>
<th>Current status</th>
<th>Evidence level</th>
<th>Recommendation level</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric/intestinal</td>
<td>Provide supportive care and prevent further injury with cessation of feeding, nasogastric decompression, and administration of intravenous fluids. Infants stay nil per os for 3–5 days in stage I, and 10–14 days in stages II and III.</td>
<td>III</td>
<td>B</td>
</tr>
<tr>
<td>decompression and bowel rest</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parenteral antibiotics</td>
<td>Broad spectrum antibiotics should be administered based on local antibiotic sensitivity patterns. Anaerobic coverage should be considered in infants with stage III NEC.</td>
<td>II-3</td>
<td>C</td>
</tr>
<tr>
<td>Primary peritoneal drainage versus exploratory laparotomy</td>
<td>Choices for surgical management in infants with NEC include peritoneal drain placement and exploratory laparotomy. In unstable premature infants with perforated NEC, peritoneal drainage can be cautiously considered as an alternative to exploratory laparotomy, although the best surgical approach in these infants remains unresolved.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td><strong>Prevention</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antenatal corticosteroids</td>
<td>Small beneficial effect of antenatal steroids for reducing risk of NEC.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>Minimal enteral (trophic) feedings</td>
<td>Infants receiving trophic feedings take less time to tolerate full enteral feeds and have a shorter duration of hospital stay, without an effect on the incidence of necrotizing enterocolitis.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Slow advancement of feedings</td>
<td>No evidence to suggest that slow advancement of enteral feed volumes reduces the risk of NEC in very low birth weight infants.</td>
<td>I</td>
<td>D</td>
</tr>
<tr>
<td>Breast milk</td>
<td>Although the mechanism of protection is not completely understood, there is strong evidence favoring the use of human milk to reduce the risk of NEC in premature infants.</td>
<td>II-2</td>
<td>A</td>
</tr>
<tr>
<td>Oral immunoglobulins</td>
<td>Data from available trials do not support oral administration of immunoglobulin for the prevention of NEC.</td>
<td>I</td>
<td>D</td>
</tr>
<tr>
<td>Enteral antibiotics</td>
<td>Enteral antibiotic treatment leads to a small reduction in NEC risk; however, increase in antimicrobial-resistant intestinal microbiota precludes routine use of this therapy.</td>
<td>I</td>
<td>D</td>
</tr>
<tr>
<td>Amino acid supplementation</td>
<td>Data are insufficient at present to support supplemental administration of parenteral L-arginine or glutamine to reduce the risk of NEC.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Recombinant cytokines and growth factors</td>
<td>Epidermal growth factor is a promising agent in preclinical studies. In early clinical studies, enteral administration of a synthetic amniotic fluid-like solution containing erythropoietin and granulocyte-colony stimulating factor has shown an encouraging safety and efficacy profile.</td>
<td>III</td>
<td>I</td>
</tr>
<tr>
<td>Probiotics</td>
<td>Probiotics may reduce the risk of severe NEC and related mortality; however, important questions remain regarding optimal choice of agent(s) and dose.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Prebiotics</td>
<td>Recent nonhuman animal experimental data suggest that oligofructose prebiotics may be useful in protecting against experimental NEC.</td>
<td>NA*</td>
<td>NA*</td>
</tr>
</tbody>
</table>

**Notes:** Insufficient human data to determine evidence level or recommendation. Levels of evidence: I, Evidence obtained from at least one properly designed randomized, controlled trial; II, evidence obtained from well-designed controlled trials without randomization (II 1), cohort or case-control analytic studies, (II 2) evidence obtained from multiple time series with or without the intervention (II 3); III, opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees. Levels of recommendations for clinical use: A, Good scientific evidence suggests that the benefits substantially outweigh the potential risks; B, at least fair scientific evidence suggests that the benefits outweigh the potential risks; C, at least fair scientific evidence suggests that there are benefits provided, but the balance between benefits and risks are too close for making general recommendations; D, at least fair scientific evidence suggests that the risks outweigh potential benefits; I, scientific evidence is lacking, of poor quality, or conflicting, such that the risk–benefit balance cannot be assessed.

**Abbreviation:** NEC, necrotizing enterocolitis.
treatment of NEC, but there is surprisingly sparse evidence guiding the choice of antimicrobial agent and duration of therapy. One study comparing alternative treatment regimens that included 90 infants with definite NEC, treated 46 cases with ampicillin and gentamicin, while 44 cases received cefotaxime and vancomycin. Infants ≥2200 g birthweight had similar outcomes with either regimen. Smaller infants given cefotaxime and vancomycin had a lower risk of culture-positive peritonitis (P = 0.01), and were less likely to die (P = 0.048) or develop thrombocytopenia (P = 0.004). These data suggest that carefully chosen antibiotic regimens can improve the outcome of NEC. Antibiotic coverage for anaerobes should be considered for infants with stage III NEC.

Surgical management
Approximately 20%–40% of patients with pneumatosis intestinalis will require surgical management. Indications for surgery include evidence of perforation seen on abdominal radiographs or positive abdominal paracentesis (stool or organism on Gram stain from peritoneal fluid). Failure of medical management, a single fixed bowel loop on radiographs, abdominal wall erythema, or a palpable mass are all relative indications for surgery. In rare cases, the entire intestine can be involved, precluding surgical intervention. Ideally, surgery should be performed after the development of bowel necrosis, but before perforation and peritonitis occurs.

In unstable premature infants with perforated NEC, peritoneal drainage can be cautiously considered as an alternative to exploratory laparotomy, although the best surgical approach in these infants remains unresolved. In the NECSTEPS trial, there was no statistically significant difference in 90-day survival, dependence on parenteral nutrition, or length of hospital stay in 117 very low birth weight infants randomly assigned to peritoneal drainage or laparotomy. However, other studies have raised important concerns about the risk of neurodevelopmental impairment following peritoneal drainage. In a recent multicenter trial, peritoneal drainage was associated with increased risk of death or neurodevelopmental impairment. A meta-analysis of three prospective observational studies and two randomized controlled trials suggested a significant excess mortality of 55% associated with peritoneal drainage. There is a need for better identification of patients who are less likely to tolerate laparotomy and who may benefit from peritoneal drainage as a temporizing strategy.

Prevention
The existing evidence shows a small beneficial effect of antenatal steroids in reducing the risk of NEC (see Table 2). This may be accomplished by accelerating maturation of the gut epithelial barrier and by reducing the overall severity of illness via prevention of lung disease. When analyzed together, eight randomized controlled comparisons of antenatal corticosteroid administration with placebo or with no treatment, including 1675 infants, showed a risk reduction in NEC of 0.46 (95% CI 0.29–0.74). Multiple courses of antenatal steroids do not appear to reduce the risk of NEC further. In a randomized trial of one to four weekly treatments of antenatal steroids or placebo that included 1858 pregnant women, and the outcomes of 2304 infants, the rate of NEC, ie, 1%, was similar in both groups.

Minimal enteral (trophic) feedings
Initiating feeds by using small amounts of milk or formula may promote the maturation of peristaltic activity and enzymatic systems, release of digestive hormones, and augment intestinal blood flow. However, in a meta-analysis of nine randomized trials including 754
very low birth weight infants, early trophic feedings did not affect feed tolerance, growth rates, or the risk of NEC (RR 1.07, 95% CI 0.67–1.70; risk difference 0.01, 95% CI −0.04–0.05).

Slow advancement of feedings

Meta-analyses of three randomized controlled trials in which a total of 396 infants were included found no significant effects of feeding advancement on the risk of NEC (RR 0.96, 95% CI 0.48–1.92) or all-cause mortality (RR 1.40, 95% CI 0.71–2.80). Infants who had slow rates of feed volume advancement took longer to regain birth weight (median difference 2–5 days) and to establish full enteral feeding (median difference 3–5 days). No statistically significant effect on total duration of hospital stay was detected. The currently available data do not provide evidence that slow advancement of enteral feed volumes reduces the risk of NEC in very low birth weight infants. Of note, few participants were extremely low birth weight or growth restricted, so conclusions about infants at greatest risk for NEC cannot be drawn from the available data.

Breast milk

Experimental and clinical studies show a protective effect of human milk feeds against NEC when compared with formula. The protective effects of breast milk against NEC are retained even in pasteurized, banked donor milk. In meta-analysis of data from five randomized trials, formula-fed infants were at higher risk of NEC than infants who received donor milk (RR 2.5, 95% CI 1.2–5.1; risk difference 0.03, 95% CI 0.01–0.06; number needed to harm 33, 95% CI 17–100). More recently, Sullivan et al showed that an exclusively human milk-based diet protected extremely premature infants against NEC and surgical NEC when compared with a mother’s milk-based diet that included bovine milk-derived human milk fortifier and preterm formula.

Oral immunoglobulins

Three trials, including a total of 2095 neonates, were reviewed together. Oral administration of IgG or an IgG/IgA combination did not result in a significant reduction in incidence of definite NEC (RR 0.84, 95% CI 0.57–1.25), suspected NEC (RR 0.84, 95% CI 0.49–1.46), need for surgery (RR 0.21, 95% CI 0.02–1.75), or death from NEC (RR 1.10, 95% CI 0.47–2.59). Based on the available trials, the evidence does not support the administration of oral immunoglobulin for the prevention of NEC.

Enteral antibiotics

To determine the effect of enteral antibiotic prophylaxis and subsequent development of NEC, five randomized controlled trials involving 456 infants were compared. Enteral antibiotic administration resulted in a significant risk reduction for NEC (RR 0.47, CI 0.28–0.78; risk difference −0.10, 0.16 to −0.04; number needed to treat 10 [6–25]). There was a statistically significant reduction in NEC-related deaths (RR 0.32, 0.10–0.96; risk difference −0.07, CI −0.13–0.01) and number needed to treat of 14 (8–100). However, concerns about the development of resistant bacteria remain, and meta-analysis revealed a borderline increase in antimicrobial-resistant intestinal microbiota with enteral antibiotic treatment.

Amino acid supplementation

Nitric oxide augments gastrointestinal perfusion, barrier function, and mucosal repair. The supplementation of L-arginine, a major substrate for nitric oxide production, appears promising in small cohorts in reducing NEC but the data are insufficient at present to support a practice recommendation. Similarly, glutamine promotes gut epithelial proliferation and barrier function in animal studies, but a larger multicenter trial of parenteral glutamine supplementation did not show a beneficial effect in reducing the incidence of NEC in preterm infants.

Probiotics

Probiotics are living microorganisms which, when ingested, can exert a health benefit beyond basic nutrition. Probiotics improve intestinal defense mechanisms, including mucosal IgA secretion, intestinal epithelial cell proliferation, and barrier function, decrease inflammation and epithelial cell apoptosis, and may be useful in preventing NEC. Alfaleh et al analyzed 16 eligible trials including 2842 infants. Included trials were highly variable with regard to enrollment criteria such as birth weight and gestational age, baseline risk of NEC in the control groups, timing, dose, formulation of the probiotics, and feeding regimens. Enteral probiotics significantly reduced the incidence of severe NEC (stage II or more, typical RR 0.35, 95% CI 0.24–0.52) and mortality (typical RR 0.40, 95% CI 0.27–0.60). Deshpande et al selected 11 of these trials involving 2176 neonates and reported a similar reduction in NEC. The frequency of NEC decreased from 6.56% (71 of 1082) in the control group to 2.37% (26 of 1094) in the probiotics-treated group. Meta-analysis using a fixed-effects model showed reduction in risk of NEC in the probiotics-treated group (RR 0.35, 95% CI 0.23–0.55; P < 0.00001).
Only four of these trials reported a significantly higher risk for NEC in the control group.\textsuperscript{174,179,180,189} The number needed to treat with probiotics to prevent one case of NEC was 25 (95% CI 17–34). Current evidence indicates that enteral supplementation with probiotics can prevent severe NEC and decrease all-cause mortality in preterm infants. However, further study is needed before routine supplementation using infant formulas with probiotics and also to determine the safety and efficacy of probiotic formulations in extremely low birth weight infants.\textsuperscript{175,192}

**Prebiotics**

Prebiotics are nondigestible dietary supplements (usually carbohydrates or mucins) which promote proliferation of beneficial commensal bacteria like *Lactobacillus* and *Bifidobacterium*. Recent experimental data suggest that oligofructose prebiotics may be protective against NEC.\textsuperscript{193–196}

**Recombinant cytokines**

Epidermal growth factor, an important component of gut secretions, human milk, and amniotic fluid, promotes epithelial proliferation, migration, and mucosal repair following injury.\textsuperscript{199} Oral administration of recombinant epidermal growth factor protects experimental animals against NEC-like lesions.\textsuperscript{198} Other studies have similarly evaluated the role of hematopoietic growth factors, such as erythropoietin and granulocyte-colony stimulating factor. We have recently shown that transforming growth factor-\(\beta\) may protect mouse pups against NEC-like injury.\textsuperscript{196} These cytokines are present in amniotic fluid and human milk, are swallowed by the fetus in large amounts,\textsuperscript{199,200} and have a demonstrated an in vitro and in vivo protective effect on gut mucosa.\textsuperscript{200–206}

**Lactoferrin**

As an addition to antibiotics, lactoferrin has been considered by some to enhance the response of the immune system when faced with sepsis. Although immune enhancement may play a role in the treatment of NEC, current data do not support the use of lactoferrin as a single agent at this time. Manzoni et al.\textsuperscript{182} randomized 472 very low birth weight infants to receive either lactoferrin alone or in combination with *Lactobacillus rhamnosus* GG. Prophylaxis with oral lactoferrin alone did not reduce the incidence of NEC (RR 0.33, 95% CI 0.09–1.17; risk difference –0.04, 95% CI –0.0–0.00), but a significant reduction in NEC was noted when lactoferrin was combined with *L. rhamnosus* GG (RR 0.05, 95% CI 0.0–0.90; risk difference –0.06, 95% CI –0.10 to –0.02; number needed to treat 17, 95% CI 10–50).

**Prognosis**

Mortality rates range between 20% and 50%. Approximately 27%–63% of affected infants may require surgery,\textsuperscript{1,16} and as many as 50% infants may die in the postoperative period.\textsuperscript{1,15,17} Subacute complications include strictures, dysmotility, malabsorption, and short gut syndrome.\textsuperscript{15} Severe NEC has been associated with growth delay that can persist beyond infancy into childhood and poor neurodevelopmental outcome at a corrected gestational age of 18–22 months.\textsuperscript{207}

**Summary**

Despite advances in the diagnosis and management of many neonatal diseases, NEC remains a devastating condition for many infants. While it is established that very low birth weight infants are at greatest risk for development of NEC, human milk-feeding appears to be the single most effective strategy to reduce, but not eliminate, this disease. Current medical management of NEC is largely supportive and likely does not modify the etiopathogenesis of the disease. Controversies remain regarding optimal surgical management for this condition. Although there are important gaps in our understanding of NEC, future research should focus on prevention of the disease and early recognition that occurs well before the onset of intestinal necrosis.

**Acknowledgment**

AM is supported by a National Institutes of Health award.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


